A rumor circulating within the industry today suggests that Bristol-Myers Squibb (BMS) China operations may undergo significant restructuring. According to purported email content, BMS has signed an agreement to sell its 60% stake in Sino-American Shanghai Squibb Pharmaceuticals (SASS), along with several associated products exclusively manufactured and sold in mainland China—including Baraclude, Bufferin, Theragran, Monopril, and Velosef—to an affiliate of Hillhouse Investment Group (Hillhouse Capital).

The transaction is expected to be completed in early 2026, though specific financial terms have not been disclosed. BMS stated in the email that "this divestiture plan reflects the company's evolving network strategy," noting that the move will help BMS concentrate internal resources on core areas with the greatest growth potential while optimizing business operations through external partnerships with local manufacturing and market expertise.

Bristol-Myers Squibb is a leading global biopharmaceutical company that entered the Chinese market in 1982, jointly establishing Sino-American Shanghai Squibb Pharmaceuticals with Shanghai Pharmaceuticals Group and Sinopharm Group. Located in Shanghai's Minhang District, the company holds historical significance as China's first Sino-American joint venture pharmaceutical enterprise following the country's reform and opening-up policy.

The acquiring party, Hillhouse Capital, is one of Asia's largest investment institutions by assets under management, adhering to a philosophy of long-term structural value investing. The firm specializes in identifying investment opportunities amid industry transformations through in-depth research. Its investment portfolio spans both primary and secondary markets across VC, PE, and buyout stages, with healthcare and pharmaceuticals being one of Hillhouse's key focus areas.